抗小鼠CD52单克隆抗体对小鼠肠道上皮内淋巴细胞的作用。

Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes.

作者信息

Qu Linlin, Li Qiurong, Jiang Haitao, Gu Lili, Zhang Qiang, Wang Chenyang, Li Jieshou

机构信息

School of Medicine, Nanjing University, Nanjing, People's Republic of China.

出版信息

Transplantation. 2009 Sep 27;88(6):766-72. doi: 10.1097/TP.0b013e3181b47c61.

DOI:10.1097/TP.0b013e3181b47c61

PMID:19920775

Abstract

BACKGROUND

CD52 monoclonal antibody (mAb) has been used therapeutically in lymphocytic leukemia, autoimmune disease, and organ transplantation. But the effect of CD52 mAb on intestinal intraepithelial lymphocytes (IELs) was unknown. The aim of this study was to assess the influence of anti-mouse CD52 mAb on IELs.

METHODS

Twenty male C57BL/6 mice were randomly assigned to a treatment or a control group. The treatment group received anti-mouse CD52 mAb (20 mug, subcutaneously), whereas the control group received the same volume of phosphate-buffered solution. On the seventh day after treatment, mice were killed, and ileum and colon were obtained for histopathology and immunohistochemistry examination, IELs were isolated for flow cytometric analysis and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis. Furthermore, the intestinal permeability was measured by lactulose-mannitol test.

RESULTS

The number and viability of IELs were decreased significantly in treatment compared with the control group. There were significant differences between the two groups considering IELs phenotypes. In addition, the proportion of apoptotic IELs in CD52 mAb treatment group was significantly higher than the control group (19.59%+/-3.13% and 2.02%+/-0.33%, respectively; P<0.05). Furthermore, lactulose-mannitol test showed a marked increase intestinal permeability after CD52 treatment (90.38%+/-5.96% and 46.02%+/-6.40%, respectively; P<0.05).

CONCLUSION

Anti-mouse CD52 mAb could induce more IELs to apoptosis and result in reducing the number of IELs, which may disrupt intestinal barrier function.

摘要

背景

CD52单克隆抗体（mAb）已被用于淋巴细胞白血病、自身免疫性疾病及器官移植的治疗。但CD52 mAb对肠道上皮内淋巴细胞（IELs）的影响尚不清楚。本研究旨在评估抗小鼠CD52 mAb对IELs的影响。

方法

将20只雄性C57BL/6小鼠随机分为治疗组和对照组。治疗组皮下注射抗小鼠CD52 mAb（20μg），而对照组注射相同体积的磷酸盐缓冲溶液。治疗后第7天，处死小鼠，获取回肠和结肠进行组织病理学和免疫组织化学检查，分离IELs进行流式细胞术分析及3-（4,5-二甲基噻唑-2-基）-2,5-二苯基四氮唑溴盐分析。此外，通过乳果糖-甘露醇试验测量肠道通透性。

结果

与对照组相比，治疗组IELs的数量和活力显著降低。两组在IELs表型方面存在显著差异。此外，CD52 mAb治疗组凋亡IELs的比例显著高于对照组（分别为19.59%±3.13%和2.02%±0.33%；P<0.05）。此外，乳果糖-甘露醇试验显示CD52治疗后肠道通透性显著增加（分别为90.38%±5.96%和46.02%±6.40%；P<0.05）。